Nature Communications · 2015 · 117 citations · 54 references
Life SciencesNeurobiologyNeuroscienceMolecular NeuroscienceNeurodegenerationNeuropharmacologyAlzheimer DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationNeuroprotectionProtein Aggregation DisordersAlzheimer Disease ProgressionAmyloid Beta AggregationAmyloid Beta PeptidesClinical SymptomsTransgenic Mouse Models
Alzheimer's disease (AD) is characterized by the transition of amyloid-β (Aβ) monomers into toxic oligomers and plaques. Given that Aβ abnormality typically precedes the development of clinical symptoms, an agent capable of disaggregating existing Aβ aggregates may be advantageous. Here we report that a small molecule, 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS), binds to Aβ aggregates and converts them into monomers. The oral administration of EPPS substantially reduces hippocampus-dependent behavioural deficits, brain Aβ oligomer and plaque deposits, glial γ-aminobutyric acid (GABA) release and brain inflammation in an Aβ-overexpressing, APP/PS1 transgenic mouse model when initiated after the development of severe AD-like phenotypes. The ability of EPPS to rescue Aβ aggregation and behavioural deficits provides strong support for the view that the accumulation of Aβ is an important mechanism underlying AD.
54
Place navigation impaired in rats with hippocampal lesions
Richard Morris, Paul Garrud, J. N. P. Rawlins et al. · Nature · 1982 · 6.4K citations
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack, David S. Knopman, William J. Jagust et al. · The Lancet Neurology · 2009 · 4.8K citations · Full text